UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 246

Sortiert nach

Clinicopathologic characterization of diffuse-large-B-cell lymphoma with an associated serum monoclonal IgM component

PloS one, 2014-04, Vol.9 (4), p.e93903

2014

Volltextzugriff (PDF)

Absolute lymphocyte count is a prognostic factor in diffuse large B‐cell lymphoma

British journal of haematology, 2008-04, Vol.141 (2), p.265-268

2008

Volltextzugriff (PDF)

The significance of serum immunoglobulin paraprotein in diffuse large B‐cell lymphoma

British journal of haematology, 2018-09, Vol.182 (5), p.741-742

2018

Volltextzugriff (PDF)

Metronomic chemotherapy for cancer treatment: a decade of clinical studies

Cancer chemotherapy and pharmacology, 2013-07, Vol.72 (1), p.13-33

2013

Volltextzugriff (PDF)

Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting

Leukemia research, 2021-05, Vol.104, p.106552-106552, Article 106552

2021

Volltextzugriff (PDF)

Peripheral blood T cell alterations in newly diagnosed diffuse large B cell lymphoma patients and their long-term dynamics upon rituximab-based chemoimmunotherapy

Cancer Immunology, Immunotherapy, 2017-10, Vol.66 (10), p.1295-1306

2017

Volltextzugriff (PDF)

The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma

Investigational new drugs, 2019-06, Vol.37 (3), p.548-558

2019

Volltextzugriff (PDF)

The immunoglobulin isotype matters in diffuse-large-B-cell lymphoma with serum paraproteinaemia

Annals of hematology, 2015-04, Vol.94 (4), p.681-682

2015

Volltextzugriff (PDF)

Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients

Oncoimmunology, 2015-03, Vol.4 (3), p.e990773-e990773

2015

Volltextzugriff (PDF)

Use of interim [18F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy

Leukemia & lymphoma, 2012-02, Vol.53 (2), p.263-269

2012

Volltextzugriff (PDF)

HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens

Digestive and liver disease, 2011-02, Vol.43 (2), p.139-142

2011

Volltextzugriff (PDF)

Hepatitis B virus infection

The New England journal of medicine, 2009-01, Vol.360 (3), p.304

2009

Volltextzugriff (PDF)

Hepatitis B Virus Infection

The New England journal of medicine, 2009-01, Vol.360 (3), p.304-306

2009

Volltextzugriff (PDF)

Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients

American journal of clinical pathology, 2004-08, Vol.122 (2), p.298-306

2004

Volltextzugriff (PDF)

Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly/FRAIL Patients, with Diffuse Large B-Cell Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.3796-3797

2022

Volltextzugriff (PDF)

‘Les liaisons dangereuses’: Hepatitis C, Rituximab and B-cell non-Hodgkin’s lymphomas

World journal of gastrointestinal pharmacology and therapeutics, 2012-04, Vol.3 (2), p.21-28

2012

Volltextzugriff (PDF)

COO, MYC / BCL2 Status and R-IPI Define a Group of Poor Prognosis DLBCL Patients in a Real-World Clinical Setting

Blood, 2019-11, Vol.134 (Supplement_1), p.1617-1617

2019

Volltextzugriff (PDF)

Prognostication of Diffuse Large B-Cell Lymphoma By Lympho2Cx Assay and BCL2 and MYC Expression: Application in a Real Life Context of 154 Patients

Blood, 2018-11, Vol.132 (Supplement 1), p.5308-5308

2018

Volltextzugriff (PDF)

Lenalidomide and Rituximab (ReRi) As Front Line Chemo-Free Therapy of Elderly Frail Patients with Diffuse Large B-Cells Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Blood, 2019-11, Vol.134 (Supplement_1), p.2880-2880

2019

Volltextzugriff (PDF)

Comparison between R-COMP and R-CHOP in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Substudy of the Elderly Project By the Fondazione Italiana Linfomi

Blood, 2021-11, Vol.138 (Supplement 1), p.2487-2487

2021

Volltextzugriff (PDF)

Definition and Validation of the New Elderly Prognostic Index (EPI) for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Geriatric and Clinical Assessment: Results of the Prospective “Elderly Project” on 1353 Patients By the Fondazione Italiana Linfomi

Blood, 2019-11, Vol.134 (Supplement_1), p.398-398

2019

Volltextzugriff (PDF)

Fluorescence in situ hybridization and conventional cytogenetics for the diagnosis of 11q23+/mll+ translocation in leukaemia

British journal of haematology, 2003-06, Vol.121 (6), p.953-955

2003

Volltextzugriff (PDF)

1 – 25 von 246

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(214)
Mit Volltextzugriff
(212)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Clinicopathologic characterization of diffuse-large-B-cell lymphoma with an associated serum monoclonal IgM component

Absolute lymphocyte count is a prognostic factor in diffuse large B‐cell lymphoma

The significance of serum immunoglobulin paraprotein in diffuse large B‐cell lymphoma

Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab: a Phase I Clinical Trial

Metronomic chemotherapy for cancer treatment: a decade of clinical studies

Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting

Peripheral blood T cell alterations in newly diagnosed diffuse large B cell lymphoma patients and their long-term dynamics upon rituximab-based chemoimmunotherapy

The metronomic all-oral DEVEC is an effective schedule in elderly patients with diffuse large b-cell lymphoma

The immunoglobulin isotype matters in diffuse-large-B-cell lymphoma with serum paraproteinaemia

Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients

Use of interim [18F]fluorodeoxyglucose-positron emission tomography is not justified in diffuse large B-cell lymphoma during first-line immunochemotherapy

HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens

Hepatitis B virus infection

Hepatitis B Virus Infection

Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients

Remarkable Remission Rate and Long-Term Efficacy of Upfront Metronomic Chemotherapy in Elderly/FRAIL Patients, with Diffuse Large B-Cell Lymphoma

‘Les liaisons dangereuses’: Hepatitis C, Rituximab and B-cell non-Hodgkin’s lymphomas

COO, MYC / BCL2 Status and R-IPI Define a Group of Poor Prognosis DLBCL Patients in a Real-World Clinical Setting

Lenalidomide and Rituximab (ReRi) As Front-Line Chemo-Free Therapy for Elderly Frail Patients with Diffuse Large B-Cell Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Prognostication of Diffuse Large B-Cell Lymphoma By Lympho2Cx Assay and BCL2 and MYC Expression: Application in a Real Life Context of 154 Patients

Lenalidomide and Rituximab (ReRi) As Front Line Chemo-Free Therapy of Elderly Frail Patients with Diffuse Large B-Cells Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Comparison between R-COMP and R-CHOP in Older Patients with Diffuse Large B-Cell Lymphoma (DLBCL): A Substudy of the Elderly Project By the Fondazione Italiana Linfomi

Definition and Validation of the New Elderly Prognostic Index (EPI) for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Geriatric and Clinical Assessment: Results of the Prospective “Elderly Project” on 1353 Patients By the Fondazione Italiana Linfomi

Fluorescence in situ hybridization and conventional cytogenetics for the diagnosis of 11q23+/mll+ translocation in leukaemia

IgM-Secreting Diffuse Large B-Cell Lymphoma (DLBCL) Is a Poor Prognostic Subset within the Non-Germinal-Centre-Type (GC-type): An Italian Multicentre Study

Suchergebnisse filtern